

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

JJ012

RRID:CVCL_D605

Type: Cell Line

Proper Citation

RRID:CVCL_D605

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_D605

Proper Citation: RRID:CVCL_D605

Description: Cell line JJ012 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Primary central chondrosarcoma

Defining Citation: [PMID:8689637](#), [PMID:10906887](#), [PMID:12168675](#), [PMID:12354749](#), [PMID:19787792](#), [PMID:22057234](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26368816](#), [PMID:26589293](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JJ012

Synonyms: JJO12, JJ

Cross References: BTO:BTO_0005168, EFO:EFO_0006604, ArrayExpress:E-MTAB-2706, BioSample:SAMN03470880, cancercellines:CVCL_D605, Cosmic:1602476, Cosmic:1992323, EGA:EGAS00001000610, GEO:GSM1676351, GEO:GSM1701681, IARC_TP53:27035, Pharmacodb:JJ012_705_2019, Wikidata:Q54898950

ID: CVCL_D605

Record Creation Time: 20220427T220650+0000

Record Last Update: 20260913T004631+0000

Ratings and Alerts

No rating or validation information has been found for JJ012.

No alerts have been found for JJ012.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lenté M, et al. (2025) Exploring adenosine analogs for chondrosarcoma therapy: In vitro and in vivo insights. Molecular therapy. Nucleic acids, 36(3), 102642.

Suh J, et al. (2024) Decoupling NAD⁺ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2 α axis. Cell reports. Medicine, 5(1), 101342.

Bernardo-Bermejo S, et al. (2023) Quantitative multiple fragment monitoring with enhanced in-source fragmentation/annotation mass spectrometry. Nature protocols, 18(4), 1296.

Lin ZS, et al. (2023) EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. eLife, 12.

Pathmanapan S, et al. (2023) Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation. Cell reports, 42(6), 112578.

Nakagawa M, et al. (2022) Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. Journal of bone oncology, 34, 100430.